Overview of Dr. Voss
Dr. Martin Voss is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Hospital for Cancer and allied Diseases. He received his medical degree from Albert Ludwigs University Faculty of Medicine and has been in practice 12 years. He is one of 497 doctors at Memorial Sloan Kettering Cancer Center and one of 89 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Oncology. He has more than 100 publications and over 500 citings.
Office
353 East 68th Street
New York, NY 10065
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2006 - 2009
Albert Ludwigs University Faculty of MedicineClass of 2005
Certifications & Licensure
FL State Medical License 2021 - Present
NY State Medical License 2009 - 2026
NJ State Medical License 2019 - 2025- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers Start of enrollment: 2013 Apr 01
- A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer Start of enrollment: 2015 Oct 01
- Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2016 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- Management of Kidney Cancer Relapse to Adjuvant Pembrolizumab: Early Insights and Questions for a Newly Emerging Space.Martin H Voss, Robert J Motzer
European Urology. 2024-12-01 - Prospective Study of Patient, Nursing, and Oncology Provider Perspectives on Telemedicine Visits for Renal Cell Carcinoma Clinical Trials.Sahil D Doshi, Andrea Knezevic, Carlene Gonzalez, Patricia Fischer, Robert Goodman
Clinical Genitourinary Cancer. 2024-11-13 - Corrigendum to "Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase II Trial" [Eur. Urol. 86(2) (2024) 90-94].Kelly N Fitzgerald, Chung-Han Lee, Martin H Voss, Maria I Carlo, Andrea Knezevic
European Urology. 2024-10-18
Journal Articles
- Checkpoint Inhibitors and Other Novel Immunotherapies for Advanced Renal Cell CarcinomaMartin H Voss, Robert J Motzer, Nature
Lectures
- Characterizing tumor immune microenvironment (TME) and outcomes for 409 patients (pts) treated on COMPARZ: Distinct clusters emphasize immune infiltration vs. angiogen...2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
- Correlation of degree of tumor immune infiltration and insertion-and-deletion (indel) burden with outcome on programmed death 1 (PD1) therapy in advanced renal cell ca...2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Authored Content
- Genomic Classifiers in Renal Cell CarcinomaFebruary 2018
Press Mentions
The Latest Breakthroughs That Could Improve Kidney Cancer TreatmentNovember 1st, 2022
ASCO GU 2020: Dr. Albiges Recounts Exciting Research in RCCMarch 25th, 2020
Kidney Cancer: Vaccine-Based ApproachesNovember 8th, 2017- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
